Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aridis Pharmaceuticals LLC

This article was originally published in Start Up

Executive Summary

Aridis Pharmaceuticals stabilizes proteins and other complex biological products, which typically must be refrigerated by encasing them in glassy matrices composed of sugar molecules that shield them from environmental stress. Recent studies reveal that high-frequency molecular vibrations that occur in the matrix can be transmitted to these packaged proteins, leading to changes in protein structure and loss of activity or, in the case of a vaccine, making them invisible to the immune system. To counter this, Aridis uses plasticizers to improve the formulations of existing drugs and vaccines.

You may also be interested in...



A Brighter Outlook for New Cystic Fibrosis Drugs

The pipeline of new medicines to combat cystic fibrosis has risen dramatically thanks to funding support from philanthropic organizations such as the Cystic Fibrosis Foundation and venture capitalists. As more compounds demonstrate proof-of-concept, look for Big Pharma to move into the area too, lured by the possibility of label expansion beyond CF into more widespread diseases such as asthma and COPD.

Start-Up Previews (05/2008)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "A Brighter Outlook for Cystic Fibrosis Drugs," features profiles of APT Pharmaceuticals, Aridis, and BioMarck Pharmaceuticals. Plus these Start-Ups Across Health Care: Cannasat, Nanobiotix, Reveal Sciences, and Vertebration.

A Brighter Outlook for New Cystic Fibrosis Drugs

The pipeline of new medicines to combat cystic fibrosis has risen dramatically thanks to funding support from philanthropic organizations such as the Cystic Fibrosis Foundation and venture capitalists. As more compounds demonstrate proof-of-concept, look for Big Pharma to move into the area too, lured by the possibility of label expansion beyond CF into more widespread diseases such as asthma and COPD.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091582

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel